Third Biosimilar Launches in the United States

Article

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

The biosimilar infliximab-abda (Renflexis) is now being commercialized in the United States following its April 2017 FDA approval.

Infliximab-abda is a tumor necrosis factor (TNF) blocker and is a biosimilar referencing infliximab (Remicade), according to a press release. It is indicated to treat Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

The biosimilar will be priced at a wholesale acquisition cost of USD $753.39, a 35% reduction to the current wholesale acquisition cost of infliximab.

“Since we were established 5 years ago, we have strived to bring high-quality treatment options at a lower cost to US patients,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in a release. “Renflexis is our first step in meeting this important commitment. We firmly believe biosimilars will play an instrumental role in making health care more accessible to patients across the US, and we will continue our relentless drive to advance one of the industry’s strongest pipelines.”

Infliximab-abda is Samsung Bioepis’ first drug to launch in the United States, according to the release.

Biosimilars are heralded as an affordable alternative to expensive biologic medications. Although they show significant potential to reduce the overall cost of treatment, prescriber uptake has been slow largely due to the current reimbursement model.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.